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mechanism underpinning hypoxia-mediated impairments of cerebrovascular function.
Thus, the purpose of the current study was to examine the influence of orally ingested
antioxidants at clinically relevant doses (vitamin C, E, and alpha-lipoic acid) on
cerebrovascular regulation at sea-level (344 m; n=12 participants) and at high altitude
(5050 m; n=9) in a randomized, placebo-controlled and double-blinded crossover
design. Hypercapnic and hypoxic cerebrovascular reactivity tests [internal carotid (ICA)
and middle cerebral artery] were conducted at sea level while global and regional
cerebral blood flow [ICA and vertebral artery flow (VA)] were assessed after 10-12
days following arrival at 5050 m. At sea level, acute administration of antioxidants did
not alter cerebral vascular reactivity (hypoxic; pre vs post [1.50.7 vs 1.20.8 %∆CBF/-
%∆SpO2; P=0.96] or hypercapnic; pre vs post [5.72.0 vs 5.81.9 %∆CBF/∆mmHg;
P=0.33]). Furthermore, global cerebral blood flow (P=0.43) as well as cerebral vascular
conductance (ICA CVC P=0.08; VA CVC P=0.32) were unaltered at 5050 m following
antioxidant administration. In conclusion, oral administration of antioxidants does not
influence cerebrovascular function or blood flow at sea-level or high altitude.
New Findings: What is the central question of the study? Does the use of antioxidants
alter cerebrovascular function and blood flow at sea-level (344 m) and/or high-altitude
(5050 m)? What is the main finding and importance? This is the first study to investigate
whether antioxidant administration alters cerebrovascular regulation and blood flow in
response to hypercapnia, acute hypoxia and chronic hypoxia in healthy humans. We
demonstrate that an acute dose of antioxidants does not alter cerebrovascular function
and blood flow at sea-level (344 m) or following 12 days at high-altitude (5050 m).
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Abstract 84 
There is evidence, albeit limited, that elevations in oxidative stress lead to impairments in 85 
cerebrovascular function in humans. The administration of antioxidants attenuates oxidative 86 
stress and may provide a mechanism of improving vascular function in situations where free 87 
radical production is excessive. One such scenario is exposure to hypoxia, where free radicals are 88 
elevated and vascular function is impaired; however, it remains to be determined if excessive 89 
oxidative stress is a relevant mechanism underpinning hypoxia-mediated impairments of 90 
cerebrovascular function. Thus, the purpose of the current study was to examine the influence of 91 
orally ingested antioxidants at clinically relevant doses (vitamin C, E, and alpha-lipoic acid) on 92 
cerebrovascular regulation at sea-level (344 m; n=12 participants) and at high altitude (5050 m; 93 
n=9) in a randomized, placebo-controlled and double-blinded crossover design. Hypercapnic and 94 
hypoxic cerebrovascular reactivity tests [internal carotid (ICA) and middle cerebral artery] were 95 
conducted at sea level while global and regional cerebral blood flow [ICA and vertebral artery 96 
flow (VA)] were assessed after 10-12 days following arrival at 5050 m. At sea level, acute 97 
administration of antioxidants did not alter cerebral vascular reactivity (hypoxic; pre vs post 98 
[1.50.7 vs 1.20.8 %∆CBF/-%∆SpO2; P=0.96] or hypercapnic; pre vs post [5.72.0 vs 5.81.9 99 
%∆CBF/∆mmHg; P=0.33]). Furthermore, global cerebral blood flow (P=0.43) as well as 100 
cerebral vascular conductance (ICA CVC P=0.08; VA CVC P=0.32) were unaltered at 5050 m 101 
following antioxidant administration. In conclusion, oral administration of antioxidants does not 102 
influence cerebrovascular function or blood flow at sea-level or high altitude. 103 
Words: 247 104 
 105 
 106 
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 109 
Introduction  110 
Oxidative stress refers to the imbalance between the production of pro-oxidants (e.g. free 111 
radicals) and available antioxidants (e.g. vitamin C). The physiological effect of oxidative stress 112 
is determined by the magnitude of this imbalance; homeostasis consists of low levels of 113 
oxidative stress (Trinity et al., 2016) while high-levels – albeit as of yet not precisely defined  114 
concentrations – are pathological and have been implicated in the structural damage and vascular 115 
dysfunction observed in multiple disease states (Ives et al., 2014; Lavi et al., 2006; Rossman et 116 
al., 2015; Ting et al., 1996).  117 
Elevated markers of oxidative stress are evident in both acute (Irarrázaval et al., 2017) 118 
and chronic hypoxia (Lewis et al., 2014), which may lead to a reduction in nitric oxide (NO) 119 
bioavailability through the interaction of NO and superoxide (i.e. free radical [O2
-
]) to form 120 
peryoxynitrite (O2
-
 + NO = ONOO
-
) (Meli et al., 2002; Thomas et al., 2008). This reduction in 121 
NO bioavailability may ultimately decrease peripheral vascular function (Green et al., 2011) as 122 
well as cerebrovascular CO2 (Smith et al., 1997) and hypoxic (Bailey et al., 2009) reactivity.  123 
Thus, as administration of antioxidants reduces overall total oxidative stress concentrations 124 
(Richardson et al., 2007) this may improve cerebrovascular function. Excessive increases in 125 
oxidative stress have been observed in clinical populations with impaired cerebrovascular 126 
reactivity to CO2 such as diabetes (Lavi et al., 2006; Ting et al., 1996) and acute ischemic stroke 127 
(Kotur-Stevuljevic et al., 2015; Reinhard et al., 2004).  128 
While animal studies have demonstrated no effect of elevated oxidative stress on 129 
cerebrovascular CO2 reactivity (e.g., experimental increases in the hydroxyl radical) (Leffler et 130 
al., 1991; Rosenblum, 1983) the limited studies conducted to date in humans indicate oxidative 131 
stress may in fact impair cerebral reactivity (Hartmann et al., 2015; Hartmann et al., 2012). 132 
Nevertheless, the paucity of data in humans (especially healthy humans) is quite surprising given 133 
the susceptibility of the brain to changes in the redox balance. Further, studies conducted to date 134 
have been methodologically limited as only data on intra-cranial cerebral blood velocity 135 
responses to antioxidants using transcranial Doppler (TCD) ultrasound have been collected. For 136 
example, in 2015, Hartmann and colleagues reported that intravenous infusion of vitamin C 137 
(three grams) reduced cerebral blood velocity during acute hypoxia in young healthy individuals. 138 
There are, however, methodological issues associated with TCD as the technique assumes the 139 
diameter of the insonated intra-cranial vessel (e.g. middle cerebral artery, [MCA]) remains 140 
constant in hypoxia (Hartmann et al., 2015). Given the recent criticisms of this assumption 141 
[reviewed in: (Hoiland & Ainslie, 2017)], further assessment of the role of antioxidants in 142 
cerebrovascular regulation is warranted where both diameter and velocity are both assessed.  143 
Using a previously validated antioxidant cocktail (Richardson et al., 2007; Wray et al., 144 
2012) combined with high resolution duplex ultrasonography, in two separate studies, we 145 
investigated if oral administration of antioxidants alters cerebral hemodynamics: (1) during acute 146 
exposure to hypercapnia and normobaric hypoxia, and (2) following a 9-day trekking ascent and 147 
subsequent12-days at high-altitude (5050 m). Both studies employed a double blinded, 148 
randomized, placebo controlled design at sea level (Study 1) and high altitude (Study 2). In 149 
Study 1, we hypothesized that the cerebral vascular response to hypercapnia and hypoxia would 150 
be reduced after the administration of oral antioxidants in young healthy subjects at sea-level. In 151 
Study 2 we anticipated that global cerebral blood flow (gCBF) would be increased following 152 
administration of oral antioxidants in young healthy subjects at high-altitude. 153 
Methods 154 
Ethical Approval 155 
All experimental procedures were approved by University of British Columbia Clinical 156 
Research Ethics Board (CREB ID: H16-00101) and the Nepal Health Research Council, and 157 
conformed to the standards set by the Declaration of Helsinki. Verbal and written consent were 158 
obtained from all participants. 159 
Study 1 – Sea-level testing (344 m): 160 
Participants 161 
Twelve healthy young individuals (age: 24±3 years of age; two females; body mass index 162 
24±2kg/m
2
) volunteered to participate in Study 1. Participants were screened to ensure reliable 163 
ultrasound measurements of the internal carotid artery (ICA). All participants were free of 164 
cardiovascular, respiratory & cerebrovascular diseases, were non-diabetic, and were not taking 165 
any prescription drugs (other than oral contraceptives n=2) at the time of participation. A dietary 166 
food restriction sheet was given to all participants so that they could avoid foods high in 167 
antioxidants and nitrates (Kapil et al., 2014).  168 
Protocol design  169 
Figure one illustrates the protocol design for studies 1 & 2. Study 1 required two separate 170 
laboratory visits that were separated by at least 48 hrs to account for adequate antioxidant 171 
washout (Bailey & Davies, 2001; Richardson et al., 2007). Participants arrived at the laboratory 172 
having abstained from caffeine for 12 hours, exercise and alcohol for 24 hours, and had fasted 173 
for 2 hours following a light meal. Upon arrival, participants were asked to lie in the supine 174 
position for 15-minutes while they were instrumented (see ‘Experimental Measures’ below).   175 
After the 15-minute rest period, baseline ventilatory, cardiovascular, and cerebrovascular 176 
data were recorded during five minutes of room air breathing. Participants then breathed on an 177 
end-tidal forcing system (see ‘Experimental Measures’ below) where their room air partial 178 
pressures of end-tidal carbon dioxide and oxygen (PETO2 and PETCO2) (e.g. PETO2 = 91.1 ± 13.0 179 
mmHg & PETCO2 = 42.4 ± 2.3 mmHg) were held constant for two-minutes. Following the two-180 
minute room air baseline period, the participants underwent five minutes of iso-oxic hypercapnia 181 
(+9 mmHg PETCO2). Cerebral blood flow (CBF) and cerebral blood velocity of the ICA and 182 
MCA, respectively, were recorded during baseline and the last minute of hypercapnia. A five-183 
minute recovery period followed the hypercapnia stage, before a second baseline was recorded 184 
for two-minutes followed by 10-minutes of isocapnic hypoxia (PETO2 = 45mmHg) with the 185 
PETO2 targeted to mimic the level of PETO2 at 5000 m based on a previous investigation by our 186 
group (Lewis et al., 2014). Ultrasound images were recorded throughout the two-minute baseline 187 
and the ten-minute trial, with the final minute used for analysis. After all measurements and 188 
recordings were completed, the participant ingested either a placebo (appearance and weight 189 
matched sugar pills) or antioxidant dose of vitamin C (500 mg), vitamin E (400 IU), and alpha 190 
lipoic acid (300 mg). A second dose (antioxidant or placebo) containing vitamin C (500 mg), 191 
vitamin E (200 IU), and alpha lipoic acid (300 mg) was ingested approximately 30-minutes after 192 
the first antioxidant dose. The use of this specific oral antioxidant dose has been previously 193 
established showing increased antioxidant levels within the blood and decreased systemic free 194 
radical-mediated lipid peroxidation (Richardson et al., 2007; Wray et al., 2012). Post-195 
drug/placebo experimentation resumed exactly 60-minutes after the second dose of either 196 
placebo or antioxidants (Bailey & Davies, 2001; Richardson et al., 2007).  197 
Study 2 - High altitude testing (5050 m): 198 
Participants 199 
Nine healthy young individuals (age: 244yrs; two females; body mass index: 200 
232kg/m2) volunteered for Study 2. All participants were born and lived close to sea-level 201 
(<1500 m). Participants were screened to ensure reliable ultrasound measurements of the ICA. 202 
All participants were free of cardiovascular, respiratory & cerebrovascular diseases, were non-203 
diabetic, and were not taking any prescription drugs or antioxidant supplements (other than oral 204 
contraceptives n=1, and IUD n=1) at the time of or prior to participation.  205 
High-altitude protocol design (Figure 1) 206 
Similar to Study 1, the design was double blinded, randomized and placebo controlled. 207 
Each laboratory visit was separated by 48 hrs to ensure adequate antioxidant washout 208 
(Richardson et al., 2007). Each trial was completed within the Ev-K2-CNR Pyramid laboratory 209 
located in Khumbu Valley, Nepal (5050 m), and this study was a part of a larger research 210 
expedition conducted between September and November of 2016 which is currently under 211 
review. In brief, ascent to the Pyramid Laboratory took place over a slow and safe 9-day trekking 212 
protocol without the use of any acute mountain sickness prophylactics (e.g., acetazolamide). 213 
Participants spent one night in Monjo (2800 m), three nights in Namche Bazaar (3400m), one 214 
night in Deboche (3820 m), and then three nights in Pheriche (4371 m) followed by the final 215 
trekking day to the Pyramid laboratory (5050 m), and 12 days after initial arrival. While at the 216 
Pyramid laboratory, participants took part in several studies that were conducted throughout the 217 
three-week period, but careful consideration of washout times and recovery meant there was no 218 
crossover between studies. Moreover, the a priori, primary research questions addressed in the 219 
current paper are novel and are exclusively dealt with in this study alone.  220 
Participants were examined after refraining from caffeine for 12 hours, exercise and 221 
alcohol for 24 hours, and were fasted for at least two hours. Participants were instrumented and 222 
cardiorespiratory measures were taken at the start of both the pre- and post-testing trials. 223 
Participants were requested to lie quietly in the supine position for 15-minutes upon arrival. 224 
Following the collection of the cardiorespiratory variables detailed below, two-minute ultrasound 225 
recordings of both the ICA and vertebral artery (VA) were obtained. Immediately following 226 
these CBF measures, similar to the study 1, participants ingested two doses of either placebo or 227 
antioxidants (vitamin C, E, alpha-lipoic acid).  228 
Experimental measures  229 
Study 1- sea-level 230 
All cardiorespiratory variables were sampled continuously throughout the protocol at 231 
1KHz via an analogue-to-digital converter (Powerlab, 16/30; ADInstruments, Colorado Springs, 232 
CO, USA). Heart rate (HR) was measured by a 3-lead electrocardiogram (ADI bioamp ML132; 233 
ADInstruments, Colorado Springs, CO, USA), and beat-to-beat blood pressure by finger 234 
photoplethysmography (Finometer PRO, Finapres Medical Systems, Amsterdam, Netherlands). 235 
The Finometer reconstructed brachial waveform was used for the calculation of mean arterial 236 
pressure (MAP) after values were back calibrated to the average of three automated brachial 237 
blood pressure measurements made over 5-minutes at rest (Tango+; SunTech, Morrisville, NC, 238 
USA). Participants’ PETCO2, and PETO2 were sampled at the mouth, and recorded by a calibrated 239 
gas analyzer (model ML206; ADInstruments, Colorado Springs, CO, USA). Ventilation (VE), 240 
tidal volume, and breathing frequency were measured by a pneumotachograph (model HR 800L, 241 
HansRudolph, Shawnee, KS, USA) connected in series to a bacteriological filter. Peripheral 242 
oxyhemoglobin saturation (SpO2), was measured using a pulse-oximeter. All data measurements 243 
were displayed on LabChart (version 7.1; ADInstruments, Colorado Springs, CO, USA), and 244 
analyzed offline. Analysis and collection of all data were performed blinded to the condition 245 
(i.e., placebo vs antioxidants). 246 
Blood velocity and vessel diameter of the ICA were measured using a 10MHz multi-247 
frequency duplex ultrasound (Terason T3200, Teratech, Burlington, MA, USA). Arterial 248 
diameter was assessed with B-mode imaging while pulse-wave mode was used to simultaneously 249 
measure peak blood velocity.  Measures of ICA blood flow (QICA) were made ipsilateral to 250 
MCA. Blood vessel diameter and velocity of ICA were measured at least 1.5 cm distal from the 251 
common carotid bifurcation to eliminate measures of turbulent and retrograde flow. Blood 252 
velocity through the right MCA (MCAv) was measured using a 2MHz transcranial Doppler 253 
ultrasound (TCD; Spencer Technologies, Seattle, WA, USA). The TCD probes were secured in 254 
place using a specialized headband (model M600 bilateral head frame, Spencer technologies, 255 
Redmond, WA, USA) using standardized techniques (described in Willie et al., 2011). 256 
In Study 1, both PETCO2 and PETO2 were controlled using a dynamic end-tidal forcing 257 
system. The system uses independent gas solenoid valves for O2, CO2, and nitrogen (N2) and 258 
controls the volume of each gas delivered into a reservoir through a mixing and humidification 259 
chamber. The PETO2, PETCO2, expiratory and inspiratory tidal volume, frequency of breathing, 260 
and minute ventilation were determined for each participant on a breath-by-breath basis in real 261 
time using custom designed software (Labview 13.0, National Instruments, Austin, TX, USA). 262 
The operation and use of our dynamic end-tidal forcing system has been previously described in 263 
detail (Tymko et al., 2016; Tymko et al, 2015). Cerebral reactivity to hypercapnia was calculated 264 
using the baseline cerebral blood flow measure subtracting the final minute of cerebral blood 265 
flow measures during hypercapnia, then dividing by the overall change in PETCO2. Similarly, the 266 
following formula was used for the calculation of hypoxic reactivity = %∆CBF/%∆SpO2.  267 
Study 2 – high-altitude  268 
Systolic, diastolic and MAP were recorded along with HR from an automated blood 269 
pressure cuff (HEM-775CAN, Omron Healthcare, Bannockburn, IL, USA). Respiratory rate and 270 
PETCO2 were measured from a portable device (EMMA, Mainstream Capnometer, Danderyd, 271 
Sweden), and SpO2 from a finger pulse oximeter (Vacu-med, Ventura, California, USA).  272 
In Study 2, ICA flow was assessed as described above. In addition, the diameter and 273 
velocity of the vertebral artery (VA) were also measured between C4-C5, C5-C6, or proximal to 274 
entry into the vertebral column. These locations were determined on an individual basis, with the 275 
same location repeated in each participant to acquire reproducible measures. The use of TCD to 276 
assess MCAv was not used in the high-altitude protocol. 277 
At high-altitude and sea-level volumetric blood flow was calculated using the following formula:  278 
                       QICA, or QVA = 
Peak Envelope Velocity
2
 * [(0.5*Diameter)2] 279 
For the high-altitude study, gCBF was calculated using the following formula: 280 
𝑔𝐶𝐵𝐹 = (𝑄𝐼𝐶𝐴 + 𝑄𝑉𝐴) ∙ 2 
Cerebrovascular conductance (CVC) was determined to account for differences in MAP 281 
during analysis of CBF responses. This was calculated for both ICA and VA (e.g., QICA/MAP 282 
and QVA/MAP). Screen capture software was used for ultrasound recordings, and video files 283 
were stored for offline analysis. Analysis videos of both the ICA and VA were recorded and 284 
analyzed while blinded to the protocol (placebo vs antioxidant). Edge detection and wall-285 
tracking software were used to determine measures of vessel diameter and peak blood velocity, 286 
at least twelve consecutive cardiac cycle were used to determine QICA and QVA (Woodman et al., 287 
2001).  288 
Data Analysis 289 
Statistical analysis for both sea-level and high-altitude were performed using IBM SPSS 290 
(Version 24, IBM statistics), and are reported as mean  standard deviation (SD). Statistical 291 
significance was assumed at P < 0.05. Data analysis was separated via the two different studies. 292 
For study 1, a two-way (Study 1: drug/placebo x time) repeated measures analysis of variance 293 
(ANVOA) were used to compare CBF and cardiovascular variables either pre/post antioxidant or 294 
placebo for both the hypoxia and hypercapnic trials. For study 2, a two-way (Study 2: drug x 295 
time) repeated measures ANOVA was used to compare CBF and cardiovascular variables with 296 
the antioxidant and placebo trial as a function of pre versus post intervention. For both studies, 297 
when interaction effects were detected pairwise comparisons were made using Bonferroni-298 
corrected t-tests. 299 
Results 300 
Study 1- Acute hypercapnia and hypoxia 301 
Cardiovascular and cerebrovascular baseline variables for placebo and antioxidant with 302 
iso-oxic hypercapnia (+9 mmHg PETCO2) and isocapnic hypoxia (45 mmHg PETO2) are 303 
presented in Table 1 and 2, respectively. Both hypercapnia and hypoxia elevated MAP, HR, and 304 
VE (P<0.05 for both trials). During the hypercapnic trials, PETO2 was maintained at each 305 
participant baseline levels (PETO2 = 92.5 vs 93.2 mmHg; P=0.77) for each testing trial. Similarly, 306 
during the hypoxic trials PETCO2 was maintained at each participant baseline levels (PETCO2 = 307 
43.0 vs 42.7 mmHg; P=0.67) for each testing trial. There were no significant differences in the 308 
magnitude of end-tidal gas manipulations between placebo and antioxidant. Hypercapnia 309 
increased QICA (P<0.001), ICAv (P=0.01), ICA diameter (P=0.001), ICA CVC (P<0.001), and 310 
MCAv (P<0.001). Similarly, QICA (P=0.01), ICAv (P=0.01), ICA diameter (P=0.001), ICA CVC 311 
(P=0.03), and MCAv (P=0.001) all increased during isocapnic hypoxia. There were no between-312 
trial (i.e., placebo vs. antioxidant) differences for any cerebrovascular variables. Figure 2 shows 313 
individual data of both hypoxic and hypercapnic reactivity within the ICA pre and post in 314 
placebo and antioxidants.  315 
Study 2- Chronic Hypoxia 316 
Cardiovascular and cerebral vascular variables are presented in Table 4. There were no 317 
significant differences in MAP or SpO2 pre-versus post administration of either antioxidants or 318 
placebo. Similarly, there was no significant changes in QICA (P=0.22), ICAv (P=0.83), ICA 319 
diameter (P=0.19), ICA CVC (P=0.07), QVA (P=0.26), VAv (P=0.20), VA diameter (P=0.11), 320 
and VA CVC (P=0.32). Figure 3 demonstrates that there were no significant alterations in gCBF 321 
following placebo or antioxidant treatment (P=0.43). 322 
Discussion 323 
This is the first study to investigate whether antioxidant administration alters 324 
cerebrovascular regulation and blood flow in response to hypercapnia, acute hypoxia, and 325 
chronic hypoxia in healthy humans. The primary findings from our study were that the 326 
administration of oral antioxidants did not alter (i) hypercapnic or hypoxic cerebrovascular 327 
reactivity at sea-level (344 m) or (ii) gCBF at high-altitude (5050 m). Collectively, these findings 328 
highlight that at both sea-level and high-altitude, acute antioxidant administration does not alter 329 
cerebral vascular function in young healthy humans. 330 
 331 
Cerebrovascular function, reactive oxygen species and antioxidants 332 
 We found no significant change in either MCAv or ICA flow reactivity to hypoxia at 333 
sea-level. A previous study performed by Hartmann et al., (2015) reported a decrease in MCAv 334 
reactivity to isocapnic hypoxia in young healthy participants following intravenous infusion of 335 
vitamin C (three grams) (Hartmann et al., 2015). Differences between the findings of Hartmann 336 
et al. (2015) and the present study may be explained by their use of TCD to obtain velocity and 337 
not flow, as recent evidence has suggested that the MCA dilates in hypoxia (Verbree et al., 338 
2014), and that just using MCAv would ultimately underestimate cerebral blood flow (Hoiland & 339 
Ainslie, 2017). In the current study, we observed dilation within the ICA during both 340 
hypercapnia and acute hypoxia trials. Although, the physical properties (i.e. anatomical size and 341 
compliance) between intracranial and extracranial compartments differ, these data alone are 342 
consistent with previous reports of dilation of the ICA as well as the MCA during changes in 343 
arterial blood gases (Hoiland, et al., 2017; Imray et al., 2014; Wilson et al., 2011). Another 344 
consideration is that Hartmann and colleagues (2015) utilized a supra-physiological intravenous 345 
dose of vitamin C (three grams vs. the upper recommended limit for daily intake of two grams). 346 
This dose was speculated to have a pro-oxidant effect, instead of antioxidant effect (Hartmann et 347 
al., 2015). The dosing strategy used within the current study is likely more physiologically 348 
relevant. Further, the use of only a water-soluble antioxidant (i.e. vitamin C), as was utilized by 349 
Hartmann and colleagues (2015), reduces aqueous superoxide and alkoxyl radicals (Bailey & 350 
Davies, 2001), but has a reduced ability to scavenge peroxyl radicals and related chain-breaking 351 
abilities (Regoli & Winston, 1999). In contrast, lipid-soluble antioxidants target peroxyl radicals 352 
(Burton & Ingold, 1989). Therefore, our current study used an antioxidant cocktail that contained  353 
water (e.g. vitamin C) and lipid (e.g. α-tocopherol) soluble chain-breaking antioxidants in 354 
combination with α-lipoic acid, a unique “ideal” antioxidant that is both water and lipid soluble 355 
(Packer et al., 1997). This dosing combination allows for greater oxidative stress scavenging, as 356 
well as previously stated this dosing has been proven to reduce oxidative stress levels within 357 
humans (Richardson et al., 2007).    358 
Similar to the hypoxia data, we found no significant change in either MCAv or ICA flow 359 
reactivity to hypercapnia at sea-level after the administration of oral antioxidants. However, there 360 
may be an equal or greater influence of other redundant and compensatory mechanisms 361 
influencing vasomotor tone within the cerebral arteries during increased alterations of arterial 362 
CO2 other than strictly NO-mediated signal transduction (Smith et al., 1997) such as 363 
prostaglandins which up-regulate cAMP causing vasodilation (Hoiland et al., 2016; Pelligrino & 364 
Wang, 1998; St Lawrence et al., 2002), cerebral autoregulation (Ogoh et al., 2010), and 365 
sympathetic activity (Peebles et al., 2012). In relation, in COPD patients, it was demonstrated 366 
using statistical covariate analysis that the elevated oxidative stress characteristic of COPD 367 
patients may underpin their impaired CO2 reactivity when compared to controls (Hartmann et al., 368 
2012). However, this study only assessed cerebral blood velocity via TCD. Thus, the lack of 369 
experimental manipulation of oxidative stress and limited technique for CBF measurement make 370 
it difficult to draw strong inferences.   371 
High altitude, cerebrovascular function, and antioxidants  372 
The novelty of this current study was that it is the first to assess gCBF after 373 
acclimatization to altitude with and without the use of antioxidants. There are well reported 374 
elevations in oxidative stress with normobaric (Irarrázaval et al., 2017) and hypobaric hypoxia 375 
(Bailey et al., 2013; Lewis et al., 2014). Therefore, it is reasonable to hypothesize that this 376 
increase in oxidative stress may, in part, be responsible for the alternations in cerebral vascular 377 
function at high altitude (Jensen et al., 1996). Within Study 2, we reported the same consistent 378 
gCBF values that were previously reported following ~ one week of acclimatization at the same 379 
altitude [e.g. 815 ± 50 ml/min (Willie et al., 2014)]. Resting CBF remained unchanged at altitude 380 
after the administration of acute oral antioxidants. As subjects were acclimatized and CBF had 381 
returned to sea-level  values (650 ± 68 ml/min) the antioxidant intervention may have had no 382 
effect as CBF was already “normal”. Whether or not chronic antioxidant supplementation 383 
throughout the overall ascent or an increased dose may have resulted in different results remains 384 
to be established. 385 
Methodological considerations  386 
Large quantities of peroxidizable polyunsaturated fatty-acid side chains and a limited 387 
antioxidant defense leave the brain highly susceptible to high levels of oxidative stress ( Bailey 388 
et al., 2009). Furthermore, there are high concentrations of iron stores (McCord & Day, 1978) in 389 
which interactions with oxidative stress may potentially lead to lipid peroxidation (Gutteridge et 390 
al., 1983). Collectively, these mechanisms may leave the brain more susceptible to oxidative 391 
stress and consequent dysfunction. Thus, it is somewhat surprising antioxidants had no effect; 392 
however, this dosage has been demonstrated to reduce oxidative stress in peripheral venous 393 
blood samples which may not be fully reflective of the cerebral vascular environment 394 
(Richardson et al., 2007). 395 
This current study was able to examine the effects of oral antioxidant supplementation on 396 
cerebrovascular regulation at both sea-level and high-altitude. As well, it implemented a double-397 
blinded, placebo controlled experimental design to account for any between-day variability 398 
unlike previous studies. There are, however, a number of limitations related to our altitude study 399 
we must acknowledge. First, with any high-altitude field study comes a number of potential 400 
confounders (e.g. altitude illness, increased sympathetic nervous activity, and subject physical 401 
conditions). Second, while the measures applied in Study 1 provide greater insight into 402 
cerebrovascular regulation, we were not able to replicate the design due to logistical issues 403 
associated with high altitude field research and only quantified resting gCBF at HA. Third, we 404 
were only able to recruit a relatively small sample size at altitude (n=9). Lastly, this study did not 405 
measure blood samples to track changes in oxidative stress both at sea-level and high-altitude; 406 
however, we chose an identical dosing strategy previously shown to increase antioxidant levels 407 
and reduce oxidative stress (Richardson et al., 2007).  408 
Conclusion 409 
In conclusion, oral administration of antioxidants does not influence cerebrovascular 410 
function and blood flow at sea-level or high altitude, respectively. 411 
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Tables: 588 
Table 1. Cerebral vascular, hemodynamics, and respiratory variables at baseline and during iso-oxic hypercapnia following 
placebo or antioxidants. All data are presented as mean  SD.  
  Placebo  Antioxidant 
  Pre Post  Pre Post 
PETCO2 
(mmHg) 
Baseline 42.4  2.3 42.3  2.0  43.4  2.1 42.9  2.2 
 CO2 52.3  2.4* 51.8  1.8*  52.8  1.8* 52.7  2.2* 
P value Pre vs Post P=0.89; CO2 P<0.05; Interaction P<0.05  Pre vs Post P=0.89; CO2 P<0.05; 
Interaction P=0.58 
VE 
(L·min
-1
) 
Baseline 13.1  3.5 14.5  5.3  13.8  4.8 14.1  4.5 
 CO2 40.0  15.1* 37.6  16.1*  38.2  13.0* 39.9  13.2* 
P value Pre vs Post P=0.84; CO2 P<0.05; Interaction P=0.40  Pre vs Post P=0.36; CO2 P<0.05; 
Interaction P=0.44 
MAP 
(mmHg) 
Baseline 89.2  11.8 88.6  9.8  91.5  8.1 91.7  13.4 
 CO2 97.8  14.0* 96.7  9.4*  96.6  6.3* 97.4  8.7 
P value Pre vs Post P<0.05; CO2 P<0.05; Interaction P<0.05  Pre vs Post P=0.64; CO2 P<0.05; 
Interaction P=0.86 
HR 
(beats·min
-1
) 
Baseline 63.7  10.9 59.5  10.4  59.9  9.4 61.2  11.9 
 CO2 74.0  13.2 68.6  16.0  68.0  9.0* 68.1  12.7* 
P value Pre vs Post P=0.09; CO2 P=0.09; Interaction P=0.79  Pre vs Post P=0.70; CO2 P<0.05; 
Interaction P=0.63 
SpO2 
(%) 
Baseline 96.4  2.8 97.7  1.2  97.8  0.7 96.4  3.7 
 CO2 96.3  2.8 97.3  0.9  97.8  0.7 96.9  0.9 
P value Pre vs Post P=0.05; CO2 P=0.98; Interaction P=0.85  Pre vs Post P=0.19; CO2 P=0.67; 
Interaction P=0.48 
QICA 
(mL·min
-1
) 
Baseline 266.8  61.2 257.6  71.1  274.5  57.2 269.1  65.4 
 CO2 415.3  86.3* 418.4  93.1*  416.8  88.7* 413.9  87.8* 
P value Pre vs Post P=0.17; CO2 P<0.05; Interaction P=0.25  Pre vs Post P=0.37; CO2 P<0.05; 
Interaction P=0.22 
ICAv 
(cm·s
-1
) 
Baseline 45.4  14.8 40.7  9.5  42.8  8.2 42.2  9.6 
 CO2 62.6  10.7* 60.0  13.7*  60.0  11.8* 60.0  10.7* 
P value Pre vs Post P=0.07; CO2 P<0.05; Interaction P=0.64  Pre vs Post P=0.88; CO2 P<0.05; 
Interaction P=0.81 
ICA diameter 
(mm) 
Baseline 5.2  0.54 5.2  0.95  5.2  0.56 5.0  0.42 
 CO2 5.3  0.46* 5.4  0.49*  5.5  0.53* 5.4  0.51* 
P value Pre vs Post P=0.99; CO2 P<0.05; Interaction P=0.08  Pre vs Post P=0.50; CO2 P<0.05; 
Interaction P=0.13 
ICA CVC 
(mL·min
-1
·mmHg
-1
) 
Baseline 3.5  1.6 3.0  0.9  2.9  0.8 2.9  1.1 
 CO2 4.3  0.9* 4.3  1.2*  4.1  1.1* 4.3  1.2* 
P value Pre vs Post P=0.21; CO2 P<0.05; Interaction P=0.19  Pre vs Post P=0.24; CO2 P<0.05; 
Interaction P=0.47 
MCAv 
(cm·s
-1
) 
Baseline 62.8  10.2 61.5  9.9  60.9  7.7 59.8  8.6 
 CO2 86.8  19.0* 84.0  14.3*  84.7  14.3* 83.3  14.1* 
P value Pre vs Post P=0.29; CO2 P<0.05; Interaction P=0.67  Pre vs Post P=0.35; CO2 P<0.05; 
Interaction P=0.82 
For both between-trial placebo or antioxidant. Significance for CO2 as a function of group is indicated by * (P < 0.05), significant 589 
difference for pre vs post as a function of group is indicated by  (P < 0.05). abbreviations. Note. - PETCO2 = end-tidal partial 590 
pressure of carbn dioxide; VE = ventilation; MAP = mean arterial pressure; HR = heartrate; SpO2 = peripheral capillary saturation of 591 
oxygen; QICA = blood flow through the internal carotid artery; ICAV = velocity of blood through the internal carotid artery; ICA CVC = 592 
internal carotid artery cutaneous vascular conductance; MCAv = blood velocity through the middle cerebral artery. 593 
 594 
 595 
 596 
 597 
Table 2. Cerebral vascular, hemodynamic, and respiratory variables at baseline and during isocapnic hypoxia following 
placebo or antioxidants. All data are presented as mean  SD.  
  Placebo  Antioxidant 
  Pre Post  Pre Post 
PETO2 
(mmHg) 
Baseline 93.5  5.5 94.9  4.0  93.3  6.5 93.7  5.1 
 Hypoxia 
(45mmHg) 
50.1  4.3* 50.4  4.2*  56.3  4.0* 50.4  4.1* 
P value  Pre vs Post P=0.22; O2 P<0.05; 
Interaction P=0.41 
 
 Pre vs Post P=0.36; O2 P<0.05; Interaction 
P=0.30  
VE 
(L·min
-1
) 
Baseline 13.7  3.6 13.6  3.8  12.6  3.8 15.7  3.3 
 Hypoxia 
(45mmHg) 
28.1  7.4* 26.9  8.7*  24.4  10.4* 28.8  11.4* 
P value  Pre vs Post P=0.51; O2 P<0.05; 
Interaction P=0.53 
 Pre vs Post P<0.05; O2 P<0.05; Interaction 
P=0.55 
MAP 
(mmHg) 
Baseline 93.8  11.4 93.8  10.7  91.8  9.6 92.3  11.0 
 Hypoxia 
(45mmHg) 
98.1  13.4* 99.3  13.7*  95.6  10.4* 97.3  9.1* 
P value  Pre vs Post P=0.85; O2 P<0.05; 
Interaction P=0.50 
 Pre vs Post P=0.83; O2 P<0.05; Interaction 
P<0.05 
HR 
(beats·min
-1
) 
Baseline 60.2  10.5 60.9  11.7  59.5  8.8 60.0  8.9 
 Hypoxia 
(45mmHg) 
73.2  16.8* 70.6  17.6*  72.2  14.7* 75.1 14.2* 
P value  Pre vs Post P=0.60; O2 P<0.05; 
Interaction P=0.13 
 Pre vs Post P=0.16; O2 P<0.05; Interaction 
P=0.33 
SpO2 
(%) 
Baseline 97.5  1.2 97.8  0.9  97.7  0.9 97.9  1.1 
 Hypoxia 
(45mmHg) 
82.7  4.9* 82.4  4.8*  82.7  4.8* 82.5  4.9* 
P value  Pre vs Post P=0.94; O2 P<0.05; 
Interaction P=0.72 
 Pre vs Post P=0.86; O2 P<0.05; Interaction 
P=0.19 
QICA 
(mL·min
-1
) 
Baseline 224.8  81.4 247.5  78.8  244.9  77.5 249.4  78.6 
 Hypoxia 
(45mmHg) 
281.8  96.1* 310.2  103.0*  298.1  83.8* 294.7  84.0 * 
P value  Pre vs Post P=0.05; O2 P<0.05; 
Interaction P=0.34 
 Pre vs Post P<0.05; O2 P<0.05; Interaction 
P=0.91 
ICAv 
(cm·s
-1
) 
Baseline 33.6  9.7 39.4  13.7  34.7  12.0 37.3  10.7 
 Hypoxia 
(45mmHg) 
40.8  13.4 43.8  14.3  43.1  17.7* 45.4  15.2* 
P value  Pre vs Post P=0.06; O2 P=0.05; 
interaction P=0.26 
 Pre vs Post P=0.06; O2 P<0.05; interaction 
P=0.82 
ICA diameter 
(mm) 
Baseline 5.2  0.59 5.2  0.50  5.2  0.44 5.1  0.50 
 Hypoxia 
(45mmHg) 
5.4  0.57* 5.4  0.53*  5.4  0.49* 5.3  0.45* 
P value  Pre vs Post P=0.75; O2 P<0.05; 
Interaction P=0.96 
 Pre vs Post P=0.17; O2 P<0.05; Interaction 
P=0.84 
ICA CVC 
(mL·min
-1
·mmHg
-1
) 
Baseline 2.4  0.9 2.7  1.0  2.5  1.1 2.6  1.2 
 Hypoxia 
(45mmHg) 
2.9  0.9 3.0  0.9  3.2  1.4* 3.2  1.2* 
P value  Pre vs Post P=0.33; O2 P=0.08; 
Interaction P=0.06 
 Pre vs Post P=0.62; O2 P<0.05; Interaction 
P=0.35 
MCAv 
(cm·s
-1
) 
Baseline 60.2  9.7 58.3  9.2  60.9  6.7 57.9  7.1 
 Hypoxia 
(45mmHg) 
67.8  12.7* 65.0  14.1*  66.8  10.2* 69.0  9.8* 
P value  Pre vs Post P=0.23; O2 P<0.05; 
Interaction P=0.25 
 Pre vs Post P=0.83; O2 P<0.05; Interaction 
P<0.05 
For both between-trial placebo or antioxidant. Significant difference with O2 is indicated by *. Significant difference between pre 598 
versus post is indicated by . Note. - PETO2 = end-tidal partial pressure of oxygen; VE = ventilation; MAP = mean arterial pressure; 599 
SpO2 = peripheral capillary saturation of oxygen; QICA = blood flow through the internal carotid artery; ICAv = velocity of blood 600 
through the internal carotid artery; ICA CVC = internal carotid artery cutaneous vascular conductance; MCAv = blood velocity 601 
through the middle cerebral artery. 602 
Table 3. Hypercapnic and hypoxic reactivity for ICA following placebo or antioxidants. Delta change between pre and post 
within both placebo and antioxidant is displayed. Data are presented as mean  SD. 
 Placebo Antioxidant 
 Pre Post ∆ Pre Post ∆ 
ICA (mL/100g/min/mmHg) 5.8  2.0 6.8  2.1 -1.0  1.7 5.7  2.0 5.8  1.9 -0.1  2.0 
P value Condition P=0.25; Pre vs Post P=0.34; Interaction P=0.33 
ICA 
(%∆CBF/%∆PETCO2) 
15.1  4.5 16.9  4.6 1.7  4.9 15.1  5.3 15.0  4.3 -0.1  5.0 
P value Condition P=0.40; Pre vs Post P=0.52; Interaction P=0.45 
ICA 
(%∆CBF/-%∆SpO2) 
1.8  0.6 1.6  0.5 -0.3  0.7 1.5  0.7 1.2  0.8 -0.3  0.5 
P value Condition P=0.46; Pre vs Pot P=0.12; Interaction P=0.96 
Note. – ICA = internal carotid artery; CBF = cerebral blood flow; SpO2 = peripheral capillary saturation of oxygen.  603 
 604 
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 606 
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 617 
 618 
 619 
 620 
 621 
 622 
Table 4. Cerebral vascular, hemodynamics, and respiratory variables upon chronic exposure to high altitude following 
placebo or antioxidants. All data presented in mean  SD. 
  Placebo  Antioxidant P value 
PetCO2 
(mmHg) 
Pre 29.7  3.1  29.2  2.6 Condition P=0.78; Pre-vs Post P=0.58; 
Interaction P=0.41 
 Post 29.2  3.0  29.3  2.3  
     
MAP 
(mmHg) 
Pre 103.5  10.8  103.2  13.1 Condition P=0.29; Pre-vs Post P=0.77; 
Interaction P=0.29 
 Post 102.0  10.3  105.8  10.3  
     
SpO2 
(% oxyhemoglobin) 
Pre 84.5  3.1  83.7  1.8 Condition P=0.90; Pre-vs Post P=1.00; 
Interaction P=0.11 
 Post 83.6  3.3  84.6  3.0  
     
QICA 
(mL·min
-1
) 
Pre 364.1  64.6  393.3  93.4 Condition P=0.73; Pre-vs Post P=0.86; 
Interaction P=0.27 
 Post 377.4  73.7  361.9  84.7  
     
ICAv 
(cm·s
-1
) 
Pre 39.6  7.1  39.7  7.8 Condition P=0.87; Pre-vs Post P=0.14; 
Interaction P=0.83 
 Post 37.5  8.1  38.0  8.1  
     
ICA diameter 
(mm) 
Pre 4.9  0.6  5.0  0.5 Condition P=0.97; Pre-vs Post P=0.63; 
Interaction P=0.18 
 Post 5.1  0.4  4.9  0.6  
     
ICA CVC 
(mL·min
-1
·mmHg
-1
) 
Pre 3.6  0.5  3.8  1.0 Condition P=096; Pre vs post P=0.76; 
Interaction P=0.08 
 Post 3.7  0.9  3.5  0.9  
     
QVA 
(mL·min
-1
) 
Pre 228.6  199.1  181.0  155.1 Condition P=0.97; Pre-vs Post P=0.56; 
Interaction P=0.26 
 Post 210.7  181.9  253.9  149.0  
     
VAv 
(cm·s
-1
) 
Pre 19.3  4.0  18.1  3.9 Condition P=0.78; Pre-vs Post P=0.42; 
Interaction P=0.20 
 Post 19.1  3.3  20.7  4.9  
     
VA diameter 
(mm) 
Pre 6.2  2.6  6.0  2.5 Condition P=0.96; Pre-vs Post P=0.54; 
Interaction P=0.11 
 Post 6.3  2.5  6.9  2.2  
     
VA CVC 
(mL·min
-1
·mmHg
-1
) 
Pre 4.0  3.9  3.1  3.0 Condition P=0.82; Pre vs post P=0.78; 
Interaction P=0.32 
 Post 3.6  3.3  4.0  2.4  
     
gCBF 
(mLmin
-1
) 
Pre 895.6  365.7  835.9  332.7 Condition P=0.65; Pre-vs Post P=0.97; 
Interaction P=0.43 
 Post 875.6  379.5  944.1  323.1  
For both between-trial placebo and antioxidant. Note. – PETO2 = end-tidal partial pressure of oxygen; MAP = mean arterial pressure; 623 
SpO2 = peripheral capillary saturation of oxygen; QICA = blood flow through the internal carotid artery; ICAV = velocity of blood 624 
through the internal carotid artery; ICA CVC = internal carotid artery cutaneous vascular conductance; QVA = blood flow through the 625 
vertebral artery; VAV = blood velocity through vertebral artery; VA CVC = vertebral artery cutaneous vascular conductance; gCBF = 626 
global cerebral blood flow.  627 
  628 
 629 
 630 
 631 
 632 
 633 
634 
Figures: 635 
Figure 1. A) Schematic of the experimental protocol for Study 1 representing sea-level (Kelowna, 344 m) measurements & 636 
B) Study 2 representing during chronic hypoxia exposure (Evr-K2-CNR pyramid laboratory, 5050 m). QICA = blood flow 637 
through the internal carotid artery. For hypercapnia end-tidal CO2 was increased 9 mmHg above baseline resting values. For 638 
hypoxia end-tidal O2 was decreased to 45 mmHg (to simulate arterial PO2 at precisely 5000m). Resting CV = cardiovascular 639 
measurements peripheral capillary saturation of oxygen (SpO2), end-tidal partial pressure of carbon dioxide (PETCO2), heart rate 640 
(HR), and mean arterial pressure (MAP). Resting CBF = resting cerebrovascular measurements of internal carotid artery (ICA) and 641 
vertebral artery (VA). 642 
 643 
Figure 2. A) Relative CBF reactivity to hypoxia in the ICA at all experimental trials at sea-level. There was no significant 644 
differences in all experimental trials at sea-level (P=0.96). B) Relative CBF reactivity to hypercapnia in the ICA at all 645 
experimental trials at sea-level. There was no significant differences in al hypercapnic experimental trials at sea-level (P=0.33). 646 
 647 
Figure 3. Global cerebral blood flow (gCBF) in all experimental trials after chronic exposure to high-altitude. The 648 
combination of both ICA and VA blood flow after chronic exposure to high-altitude. There was no significant differences in all 649 
experimental trials at high-altitude (P=0.43). 650 
 651 
Figure 1.652 
 653 
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 655 
Figure 3.  656 
